Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)174.15
  • Today's Change4.25 / 2.50%
  • Shares traded330.63k
  • 1 Year change+156.18%
  • Beta0.6223
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Ucb SA's revenues fell -4.80% from 5.52bn to 5.25bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 418.00m to 343.00m, a -17.94% decrease.
Gross margin67.80%
Net profit margin4.40%
Operating margin8.20%
Return on assets1.55%
Return on equity2.67%
Return on investment1.88%
More ▼

Cash flow in EURView more

In 2023, Ucb SA did not generate a significant amount of cash. However, the company earned 761.00m from its operations for a Cash Flow Margin of 14.49%. In addition the company used 440.00m on investing activities and also paid 308.00m in financing cash flows.
Cash flow per share4.78
Price/Cash flow per share35.38
Book value per share47.19
Tangible book value per share-2.95
More ▼

Balance sheet in EURView more

Ucb SA has a Debt to Total Capital ratio of 25.34%, a lower figure than the previous year's 28.99%.
Current ratio1.19
Quick ratio0.7806
Total debt/total equity0.3394
Total debt/total capital0.2534
More ▼

Growth rates in EUR

Year on year, growth in dividends per share increased 2.26% while earnings per share excluding extraordinary items fell by -18.48%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.11%
Div growth rate (5 year)2.36%
Payout ratio (TTM)105.00%
EPS growth(5 years)-16.00
EPS (TTM) vs
TTM 1 year ago
-27.96
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.